ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1057

A Specific Inhibitor of Spleen Tyrosine Kinase, PRT062607, Is a Potent Modulator of Innate Immune Cell Function

Lynn A. Kamen1, Gillian Stephens1, Anjali Pandey2 and Uma Sinha1, 1Biology, Portola Pharmaceuticals, South San Francisco, CA, 2Chemistry, Portola Pharmaceuticals, South San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: macrophages, neutrophils and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tumor Necrosis Factor-α (TNF-α) is an essential component of the inflammatory stimuli leading to rheumatoid arthritis (RA).  Therapeutics targeting TNF-α are the standard of care but are not always capable of inhibiting disease progression.  Thus, there is an unmet need for novel targets for treatment of RA.  Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that plays an important role in phagocyte (macrophage and neutrophil) activation.  Phagocytes are known to be important in the pathology of RA; the purpose of this study was to evaluate the impact of Syk inhibition in modulating phagocyte activation. 

Methods: Macrophages were generated by culturing peripheral blood monocytes from healthy human volunteers with M-CSF (5ng/mL) for five days. Neutrophils were isolated from human peripheral blood on a Ficoll gradient and separated from erythrocytes via dextran sedimentation.  As a surrogate for pathogenic autoantibodies in the arthritic synovial joint, immune complex was used for activation of macrophages and neutrophils.  Immune complex was prepared by preincubating chicken egg ovalbumin with goat anti-chicken egg ovalbumin IgG  at 370C.  To mimic integrin-mediated activation, plate-bound poly-RGD (20 µg/mL) was used as a stimulus.  TNF-α release from macrophages was measured via ELISA (R and D Systems).  The SOD-inhibitable oxidative burst response in neutrophils was measured through cytochrome c reduction in a plate-based absorbance assay. Specific Syk inhibitor, PRT062607 (P505-15) was added in vitro to the experimental system containing human macrophages or neutrophils.

Results: Syk inhibition by PRT062607 suppressed inflammatory cytokine release. Cytokine levels, as measured by TNF-α release from macrophages stimulated with immune complex, was potently inhibited by PRT062607 (IC50=0.070µM). Furthermore, PRT062607 treatment was a potent inhibitor of neutrophil-mediated superoxide production in response to various physiologically relevant stimuli (integrin ligation IC50=0.037µM and immune complex stimulation IC50=0.195µM). Interestingly TNF-α alone was able to facilitate neutrophil-mediated superoxide production, and this activity was potently suppressed by PRT062607 (IC50=0.065µM). 

Conclusion: Together these data indicate a novel role for Syk inhibition in controlling TNF-α-mediated inflammation.  These results suggest that in addition to decreasing immune cell activation and inflammation in the joint, Syk inhibition could also partly mimic the effects of an anti- TNF-α therapy.  Thus, Syk inhibition by a small molecule kinase inhibitor has the potential to be a novel mode of therapy in RA.


Disclosure:

L. A. Kamen,

Portola Pharmaceuticals Inc,

1;

G. Stephens,

Portola Pharmaceuticals,

3;

A. Pandey,

Portola Pharmaceuticals,

1;

U. Sinha,

Portola Pharmaceuticals,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-specific-inhibitor-of-spleen-tyrosine-kinase-prt062607-is-a-potent-modulator-of-innate-immune-cell-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology